New biologic shows promise for rare inflammatory disease in japan
NCT ID NCT04717635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested canakinumab, an anti-inflammatory biologic, in 14 Japanese adults with Adult-Onset Still's Disease (AOSD), a rare condition causing fevers and joint pain. Participants received injections every 4 weeks for at least 48 weeks. The goal was to see if the drug could improve symptoms and help patients reduce their steroid use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- canakinumab (a biologic drug that blocks inflammation)
- What this could lead to
- If it works, this could provide a new treatment option for Japanese patients with Adult-Onset Still's Disease, helping control symptoms and reduce steroid use.
- What could go wrong
- This was a small, single-arm study with only 14 participants, so results may not apply broadly. As a biologic, canakinumab carries risks like increased infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT ONSET STILL'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Chiba, Chiba, 260 8677, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 0608648, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa-ku, 236-0004, Japan
-
Novartis Investigative Site
Iruma-gun, Saitama, 3500495, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 1138655, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 1048560, Japan
-
Novartis Investigative Site
Mitaka, Tokyo, 181-8611, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, 1608582, Japan
-
Novartis Investigative Site
Ishikawa, 9208641, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.